Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.

Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.

J Am Soc Nephrol. 2019 Jun 14. pii: ASN.2019050450. doi: 10.1681/ASN.2019050450. [Epub ahead of print]

PMID:
31201218
2.

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.

Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20.

PMID:
31110051
3.

Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review.

Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB.

Pharmacoecon Open. 2019 Apr 9. doi: 10.1007/s41669-019-0132-5. [Epub ahead of print] Review.

4.

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.

Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB.

J Med Econ. 2019 Jun;22(6):593-604. doi: 10.1080/13696998.2019.1588738. Epub 2019 Mar 27.

PMID:
30813807
5.

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.

Ramachandran P, Morcus R, Tahir M, Onukogu I, Spinowitz B, Wang JC.

J Med Case Rep. 2018 Oct 19;12(1):303. doi: 10.1186/s13256-018-1849-y. Review.

6.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

7.

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.

Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1163-1170. doi: 10.1093/ndt/gfy127.

8.

Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.

Fishbane S, Spinowitz B.

Am J Kidney Dis. 2018 Mar;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026. Epub 2018 Jan 11.

PMID:
29336855
9.

One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.

Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1918-1926. doi: 10.1093/ndt/gfw460.

PMID:
28339993
10.

Pernicious Anemia Associated Cobalamin Deficiency and Thrombotic Microangiopathy: Case Report and Review of the Literature.

Yousaf F, Spinowitz B, Charytan C, Galler M.

Case Rep Med. 2017;2017:9410727. doi: 10.1155/2017/9410727. Epub 2017 Feb 6.

11.

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.

Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.

Kidney Int. 2016 Nov;90(5):1115-1122. doi: 10.1016/j.kint.2016.07.019. Epub 2016 Sep 17.

12.

Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Yousaf F, Spinowitz B.

Curr Hypertens Rep. 2016 Mar;18(3):23. doi: 10.1007/s11906-016-0629-6. Review.

PMID:
26894597
13.
14.

Novel Agents for the Prevention and Management of Hyperkalemia.

McCullough PA, Costanzo MR, Silver M, Spinowitz B, Zhang J, Lepor NE.

Rev Cardiovasc Med. 2015;16(2):140-55. Review.

PMID:
26198561
15.

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group.

Nephrol Dial Transplant. 2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16.

16.

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B.

JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in text.

PMID:
25402495
17.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S; PEARL Study Groups.

N Engl J Med. 2013 Jan 24;368(4):320-32. doi: 10.1056/NEJMoa1203166.

19.

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.

Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.

Hemodial Int. 2010 Apr;14(2):233-9. doi: 10.1111/j.1542-4758.2009.00421.x. Epub 2009 Nov 3.

PMID:
19888948
20.
21.

Ferumoxytol for treating iron deficiency anemia in CKD.

Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ.

J Am Soc Nephrol. 2008 Aug;19(8):1599-605. doi: 10.1681/ASN.2007101156. Epub 2008 Jun 4.

22.

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M; Epoetin Alfa Extended Dosing Study Group.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1015-21. doi: 10.2215/CJN.05681207. Epub 2008 Apr 9.

23.

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta.

Spinowitz BS.

Haematologica. 2008 May;93(5):761-4. doi: 10.3324/haematol.10985. Epub 2008 Mar 26.

24.

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U; RUBRA Study Investigators.

Am J Nephrol. 2008;28(2):280-9. Epub 2007 Nov 13.

PMID:
18004064
25.

Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.

Spinowitz BS, Pratt RD; Epoetin Delta 2002 Study Group.

Curr Med Res Opin. 2006 Dec;22(12):2507-13.

PMID:
17166333
26.

The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.

Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M.

Kidney Int. 2005 Oct;68(4):1801-7.

27.

Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.

Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS.

Nephron Clin Pract. 2004;96(2):c63-6.

PMID:
14988600
28.

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group.

Am J Nephrol. 2004 Jan-Feb;24(1):32-40. Epub 2003 Dec 17.

PMID:
14685005
29.

Prediction of single-pool Kt/v based on clinical and hemodialysis variables using multilinear regression, tree-based modeling, and artificial neural networks.

Goldfarb-Rumyantzev A, Schwenk MH, Liu S, Charytan C, Spinowitz BS.

Artif Organs. 2003 Jun;27(6):544-54.

PMID:
12780509
30.

Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.

Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N.

Am J Kidney Dis. 2000 Jul;36(1):88-97.

PMID:
10873877
31.

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS.

Control Clin Trials. 1999 Oct;20(5):493-510.

PMID:
10503809
32.

Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.

Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS.

Am J Nephrol. 1998;18(6):498-503.

PMID:
9845824
33.

Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.

Schwenk MH, Jumani AQ, Rosenberg CR, Kulogowski JE, Charytan C, Spinowitz BS.

Pharmacotherapy. 1998 May-Jun;18(3):627-30.

PMID:
9620114
34.

Fluoxetine in depressed patients on dialysis.

Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RF.

Int J Psychiatry Med. 1997;27(1):71-80.

PMID:
9565715
35.

Fractional direct dialysis quantification: a new approach for prescription and monitoring hemodialysis therapy.

Charytan C, Gupta B, Meindel N, Spinowitz B.

Kidney Int. 1996 Dec;50(6):1845-9.

36.

Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.

Gupta BK, Spinowitz BS, Charytan C, Wahl SJ.

Am J Kidney Dis. 1993 Jun;21(6):659-62.

PMID:
8503421
37.

Dialysis adequacy in hypoalbuminemic continuous ambulatory peritoneal dialysis patients.

Spinowitz BS, Gupta BK, Kulogowski J, Charytan C.

Perit Dial Int. 1993;13 Suppl 2:S221-3.

PMID:
8399571
38.

Dialysis adequacy versus metabolic factors in the clinical assessment of CAPD.

Spinowitz BS, Gupta BK, Kulogowski J, Galler M, Golden R, Rascoff J, Charytan C.

Adv Perit Dial. 1993;9:295-8.

PMID:
8105947
39.

Impact of epoetin beta on dialyzer clearance and heparin requirements.

Spinowitz BS, Arslanian J, Charytan C, Golden RA, Rascoff J, Galler M.

Am J Kidney Dis. 1991 Dec;18(6):668-73.

PMID:
1962651
40.

Transfusion therapy: associated risks and alternative approaches.

Picard VT, Sayers MH, Spinowitz BS, Richner RE.

ANNA J. 1990 Dec;17(6):457-64.

PMID:
2256728
41.

Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients.

Deniston OL, Luscombe FA, Buesching DP, Richner RE, Spinowitz BS.

ASAIO Trans. 1990 Jul-Sep;36(3):M157-60.

PMID:
2123632
43.

The practical aspects of therapy with rHuEPO.

Spinowitz B.

Am J Nephrol. 1990;10 Suppl 2:24-8.

PMID:
2260614
44.

The existence of a protracted course in crescentic glomerulonephritis.

Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B.

Kidney Int. 1987 Mar;31(3):790-4.

45.

Subclavian vein stenosis as a complication of subclavian catheterization for hemodialysis.

Spinowitz BS, Galler M, Golden RA, Rascoff JH, Schechter L, Held B, Charytan C.

Arch Intern Med. 1987 Feb;147(2):305-7.

PMID:
3813748
46.

Comparison of eosinophilia in patients undergoing peritoneal dialysis and hemodialysis.

Backenroth R, Spinowitz BS, Galler M, Golden RA, Rascoff JH, Charytan C.

Am J Kidney Dis. 1986 Sep;8(3):186-91.

PMID:
3752073
48.

Nondilated obstructive nephropathy.

Rascoff JH, Golden RA, Spinowitz BS, Charytan C.

Arch Intern Med. 1983 Apr;143(4):696-8.

PMID:
6838293
49.

Percutaneous transluminal dilatation for vascular access.

Spinowitz BS, Carsen G, Meisell R, Charytan C.

Nephron. 1983;35(3):201-4.

PMID:
6226882
50.

Technique for implantation of the Toronto-Western catheter at the Booth Memorial Medical Center.

Fink S, Spinowitz BS, Charytan C.

Clin Exp Dial Apheresis. 1982;6(4):193-5.

PMID:
7182085

Supplemental Content

Loading ...
Support Center